Subcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA)

Official title

Effect of Subcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA): A Randomized, Double-Blind, Placebo-Controlled Trial

Overview

This is a trial of tirzepatide in people with obesity and knee osteoarthritis. The main purpose of this study is to see if tirzepatide can reduce number of these participants who require a knee replacement. Participants will be randomized to take a weekly injection of tirzepatide or a placebo for a total of 72 weeks.

Interventions

• Drug Tirzepatide
  Participants will receive tirzepatide subcutaneously
• Drug Placebo
  Participants will receive placebo subcutaneously

Primary outcome measures

• Percentage of patients who undergo knee replacement in the target joint [Time frame: within 72 weeks of randomization]

Secondary outcome measures (12)

• Osteoarthritis Pain [Time frame: Baseline, Week 72]
• Osteoarthritis Function [Time frame: Baseline, Week 72]
• Osteoarthritis Stiffness [Time frame: Baseline, Week 72]
• Percentage change in bodyweight [Time frame: Baseline, Week 72]
• ≥5% body weight reduction [Time frame: Baseline, Week 72]
• ≥10% body weight reduction [Time frame: Baseline, Week 72]
• ≥20% body weight reduction [Time frame: Baseline, Week 72]
• Physical Health [Time frame: Baseline, Week 72]
• Mental Health [Time frame: Baseline, Week 72]
• Physical Activity [Time frame: Baseline, Week 72]
• Non-opioid prescription pain medication use [Time frame: Baseline, between 68-72 weeks]
• Opioid prescription pain medication use [Time frame: Baseline, between 68-72 weeks]

Eligibility criteria

Inclusion criteria

• Have a body mass index of ≥ to 30 kg/m2.
• Report one or more previous unsuccessful attempt to lose body weight via lifestyle modification.
• Have been deemed eligible to enter the waiting list for primary knee replacement for the treatment of osteoarthritis in the target joint by an orthopaedic surgeon at one of the participating study sites.
• Have moderate-to-severe knee osteoarthritis in the target joint, defined as a Kellgren-Lawrence grade two or greater.
• Be willing to and capable of learning how to self-inject the study drug and follow study procedures for the duration of the trial.
• Provide informed consent to study participation in line with the requirements of the human research ethics committee of the study site.

Female participants must:

• Not be currently pregnant or breastfeeding AND
• Not be of reproductive potential, defined as:
• Infertile due to surgical sterilization or congenital anomaly, OR
• Post-menopausal defined as:
• A woman over the age of 40 years with spontaneous cessation of menses for at least 12 consecutive months (in the absence of medications known to induce amenorrhea), with a follicle-stimulating hormone ≥40mIU/mL, and a negative pregnancy test prior to study entry, OR
• A woman over the age of 55 years with cessation of menses for at least 12 consecutive months (in the absence of medications known to induce amenorrhea), OR
• A woman over the age of 55 years that has commenced hormone replacement therapy after a documented diagnosis of menopause.

Exclusion criteria

Participant will be ineligible for inclusion if they meet any of the following criteria:

• Have been deemed eligible to enter the waiting list for knee replacement in the contralateral knee by an orthopaedic surgeon at one of the participating study sites.
• Have used any prescription medications intended to promote weight loss (e.g., tirzepatide, liraglutide, semaglutide) in the three months prior to screening.
• Have previously undergone any surgical or endoscopic procedure intended to promote weight loss.
• Have been diagnosed with type 1 diabetes mellitus (T1DM) or T2DM
• Have laboratory evidence indicative of diabetes mellitus during screening.
• Have personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• Have an active malignancy (excluding basal or squamous cell skin cancer).
• Have had a transplanted organ or awaiting an organ transplant
• Have received chronic systemic glucocorticoid therapy (for more than 14 days) in prior 3 months or have a significant, active autoimmune abnormality (e.g., lupus or rheumatoid arthritis) that the study doctor deems likely to require systemic glucocorticoid therapy during the next 18 months.
• Have any other medical conditions, abnormal laboratory tests or concomitant medications that make them unsuitable for participation:

• Have a clinically significant gastric emptying abnormality.
• Have had a history of acute or chronic pancreatitis.
• Have obesity induced by other endocrinologic disorders
• Have an unstable psychiatric disorder
• Have a Patient Health Questionnaire (PHQ-9) score of >15 during screening
• Have been deemed by the study doctor to be actively suicidal,
• Have answered "yes" to questions 4 or 5 on the "Suicidal Ideation" section of the Columbia-Suicide Severity Rating Scale (C-SSRS) during screening, OR
• Have answered yes to any questions in the "Suicidal Behaviour" section of the C-SSRS during screening. AND
• The behaviour or ideation occurred in the last month

• Have uncontrolled hypertension (systolic blood pressure above or equal to 160 mmHg and/or diastolic blood pressure above or equal to 100 mmHg)
• Have had within the past 6 months prior to randomisation any of the following: acute myocardial infarction, cerebrovascular accident, unstable angina, or hospitalisation due to congestive cardiac failure (are also exclusion criteria for elective knee replacement)
• Have severe renal impairment defined as an eGFR <30 mL/min/1.73 m2 at screening visit.
• Have thyroid-stimulating hormone outside of the range of 0.4 to 6.0 mIU/L at screening visit
• Have acute or chronic hepatitis or abnormal liver function tests as measured by either alanine aminotransferase or alkaline phosphatase >200 IU.
• Have any other known contraindication to any glucagon-like peptide-1 receptor agonists.
• Are study site personnel, or immediate family of a member of the study site.
• Have been enrolled in any other study of an investigational product within the past ninety days or are currently enrolled in such a study.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Quadruple blind

Primary purpose

Treatment

Study locations

Australia · 4 centers

• St Vincents Hospital Melbourne — Fitzroy
• Western Health — Melbourne
• Austin Health-Repatriation Hospital — Melbourne
• Eastern Health — Melbourne

Publications

• Ursini F, Ciaffi J, Caporali R. If the evidence is there, why are GLP-1 receptor agonists not on-label for hip and knee osteoarthritis in overweight patients? RMD Open. 2025 Sep 23;11(3):e006025. doi: 10.1136/rmdopen-2025-006025. PMID 40992788

Identifiers

NCT: NCT06191848 · 75430

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗